Results 151 to 160 of about 775,220 (247)

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione‐Mediated Stemness Maintenance

open access: yesAdvanced Science, EarlyView.
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li   +17 more
wiley   +1 more source

Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation

open access: yesAdvanced Science, EarlyView.
Oxidative phosphorylation (OXPHOS) activity serves as a critical metabolic determinant of radiotherapy outcomes in esophageal squamous cell carcinoma (ESCC). The CEBPB/AREG/EREG axis drives radioresistance in ESCC by reprogramming OXPHOS. AREG and EREG function as predictive biomarkers for nCRT response and prognosis of ESCC patients.
Zhang Lin   +15 more
wiley   +1 more source

Axillary tumor deposits in primary breast carcinoma: a case report. [PDF]

open access: yesJ Med Case Rep
Mokni W   +4 more
europepmc   +1 more source

Mucinous Carcinoma of the Breast Accompanied by Coarse Calcification

open access: diamond, 2012
Hitomi Tani   +5 more
openalex   +2 more sources

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

open access: yesAdvanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao   +16 more
wiley   +1 more source

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

open access: yesAdvanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy